Broker tips: IMI, Bodycote, IQE, Easyjet

Alexander Bueso WebFG News | 04 Dec, 2017 21:12 | | |

ep avioneasyjet 20171121090302
Avión de easyJetEUROPA PRESS

Deutsche Bank upgraded its stance on IMI on Monday and downgraded Bodycote as it took a look at the European capital goods sector.

The bank expects sector growth to peak around the first quarter of 2018 as Chinese economic data show signs of weakening and comps get tougher for short-cycle businesses.

"Given we already need to look beyond 2018 for valuation support, we expect later cycle companies with exposure to process/hybrid industries (international O&G, petrochem, copper mining, food & beverage, etc) to perform better," it said.

Deutsche Bank upgraded its stance on IMI to 'buy' from 'hold' and lifted its price target to 1,475p from 1,285. The bank said it estimates around 40% of IMI is exposed to late cycle markets, predominantly at Critical, with this division bottoming in 2017 and offering scope for recovery surprise across margin and revenue as it rebounds over the next 18-24 months.

In, addition, it pointed to an undemanding valuation versus sector, with 12-month forward price-to-earnings seeing no sector relative re-rating. It also said that M&A remains firmly on the agenda, which will supplement organic growth.

It downgraded Bodycote to 'hold' from 'buy' but left the price target unchanged at 990p.

Trading on 24 times' their estimates for its earnings per share in 2020, stock in IQE was on a 'premium' valuation but it did not look stretched, analysts at Barclays said.

In particular, the sole supplier of epitaxial wafers to Apple was set to see "substantial" near-term growth in the market for 3D sensors, the analysts said.

Reflecting that, the stock had run-up by 359% year-to-date.

Even so, given their estimates for a compound annual rate of growth in EPS of nearly 40%, Barclays sounded a bullish note, initiating coverage at 'overweight' and setting a target price of 210p.

Analysts at Morgan Stanley hiked their target price on Shares of Easyjet on the back of improved estimates for the airline's revenues per seat and higher projections for the cable exchange rate together with the impact from 'rolling forward' their valuation at improved multiples.

In particular, Easyjet's RPS were now seen growing by 2% in fiscal years 2018 and 2019 while the pound was seen trading at an average level of 1.33 against the US dollar, up from 1.31 previously.

Hence, the broker's estimates for the company's profits before tax in fiscal years 2019-2020 received a boost of between 2% to 5%.

Morgan Stanley added: "With encouraging revenue trends as a result of capacity leaving the market, and solid ancillary growth, we roll forward our valuation from FY18 to FY19 and update our EV/EBITDAR multiple from 8xto 9x, now at the mid-point of its 10 year historic trading range."

More news

18:02 Europe close: Technology and M&A power gains in shares

Stocks on the Continent gained ground on Tuesday paced by Technology issues, even as traders waited on the US central bank's policy announcement the next day.

17:53 London close: Forties failure lifts FTSE as inflation spikes

London stocks extended their gains on Tuesday as supply disruptions boosted the energy sector and investors mulled higher than expected UK inflation figures.

17:33 US open: Boeing, 3M push Dow Industrials to fresh record-high

Wall Street's main indices are again heading higher on Tuesday as the Federal Reserve kicks off its two-day rate-setting meeting and several positive updates from corporate heavyweights such as Boeing and 3M.

17:34 EasyJet acquisition of Air Berlin assets approved by European Commission

UK budget airline easyJet cleared a major regulatory hurdle on Tuesday as its proposed acquisition of airport slots and aircraft from Air Berlin was approved by the European Commission.

17:49 Facebook to overhaul its tax structure worldwide

Facebook will move its global tax and revenue base from Ireland and begin booking advertising locally in every country where it operates.

16:51 GSK given green light for Churg-Strauss syndrome treatment

GlaxoSmithKline has been given approval by the US drug regulator for a first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.

16:44 Trump accuses Democrats of plot after sexual harassment claims

US President Donald Trump has claimed Democrats are behind a series of sexual harassment claims made against him this week.

16:41 Trump vows to send American astronauts to the moon

Donald Trump, the President of the United states signed the Space Policy Directive 1 to send astronauts to the moon again and to Mars for the first time in history.

16:33 Goldman Sachs keeps Barclays and Lloyds at 'sell'

Goldman Sachs reiterated its 'sell' recommendation on shares of Lloyds and Barclays, placing both stocks on its list of 'UK Sell Ideas' for 2018.

16:27 EU Brexit negotiator says David Davis comments 'undermine trust'

Brexit secretary David Davis’ claim that the deal agreed by the UK and European Union last week is not binding has been branded “unacceptable” by bloc negotiator Guy Verhofstadt, who added that it “undermines trust” between the two teams.